In the OASIS 4 Phase 3 trial, it produced 13.6% mean weight loss at 64 weeks in the treatment-policy analysis, and 16.6% among patients who fully followed the protocol (Wharton et al., NEJM 2025)
Your altRx membership includes telehealth consultations with a licensed provider, a personalized care plan, prescription fulfillment if appropriate, and shipping
Additionally, Retatrutide promotes DNA repair mechanisms & inhibits the accumulation of senescent cells, thereby delaying age-related functional decline
Food tolerability improves
Now, could they take the medication for a different period of time and have more lasting weight loss
The dual GIP/GLP-1 approach is what set tirzepatide apart from the earlier single-target GLP-1 agonists